Johnson & Johnson $JNJ Shares Sold by Waypoint Wealth Partners Inc.

Key Points

• Waypoint Wealth Partners Inc. reduced its shares in Johnson & Johnson by 18% in the 2nd quarter, now holding 9,913 shares valued at approximately $1.51 million.
• Several institutional investors have increased their stakes in Johnson & Johnson, with Lantz Financial LLC boosting its position by 3.3% and Apexium Financial LP by 10.7% in the first quarter.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, translating to an annualized dividend of $5.20 and a yield of 3.0%, with a payout ratio of 55.61%.

Waypoint Wealth Partners Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,913 shares of the company's stock after selling 2,180 shares during the quarter. Johnson & Johnson makes up approximately 0.4% of Waypoint Wealth Partners Inc.'s portfolio, making the stock its 26th biggest position. Waypoint Wealth Partners Inc.'s holdings in Johnson & Johnson were worth $1,514,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter valued at $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.0%

Shares of JNJ traded up $1.81 on Friday, hitting $175.97. 25,617,065 shares of the stock traded hands, compared to its average volume of 6,995,150. The company has a market capitalization of $423.80 billion, a PE ratio of 18.82, a P/E/G ratio of 2.22 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business has a 50 day simple moving average of $172.80 and a 200 day simple moving average of $161.69. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.0%. Johnson & Johnson's payout ratio is presently 55.61%.

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday. Guggenheim restated a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Finally, Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $177.87.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.